Quemliclustat not checked
Arcus Biosciences · AB680
FollowEvery change as it happens, and a Monday email
Trials
2 active
9 in total · 4 in the EU
What this is
- How it works
- How it works isn't classified yet
- Main trialPhase 3
- “The purpose of this study is to compare overall survival of quemliclustat, nab-paclitaxel and gemcitabine versus placebo, nab-paclitaxel and gemcitabine in all randomized patients.”In the company’s words, NCT06608927 on ClinicalTrials.gov
- Other names
- AB680
Other drugs for Metastatic Pancreatic Ductal Adenocarcinoma
- CAM2029Camurus AB · Phase 3
- Immuncell-LCGC Cell Corporation · Phase 3
- RYZ101RayzeBio, Inc. · Phase 3
- XNW28012Evopoint Biosciences Inc. · Phase 3
- IvonescimabAkeso · Summit Therapeutics · Phase 3
- DaraxonrasibRevolution Medicines · Phase 3
Coming up2
- Dec 2027Phase 2 trial completes · ClinicalTrials.gov
- 30 Nov 2030Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials9
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 30 Nov 2030 | Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma | |
| Phase 2Active, not recruiting | Dec 2027 | Study With Various Immunotherapy Treatments in Participants With Lung Cancer | |
| Phase 2Completed | 7 Sep 2026 | A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies | |
| Phase 1/2Completed | 30 Aug 2024 | Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer | |
| Phase 1/2Completed | 5 Sep 2025 | An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer. | |
| Phase 1Completed | 19 Aug 2019 | A Study to Investigate the Safety of AB680 in Healthy Volunteers | |
| Phase 1Completed | 22 Sep 2021 | A Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy Volunteers | |
| Phase 1Completed | 6 Apr 2026 | Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24) | |
| Phase 1Completed | 21 Jul 2026 | A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026